

Genome-scale metabolic network reconstruction of model animals as a platform for translational research

Hao Wang^{a,b,c}, Jonathan L. Robinson^{a,b}, Pinar Kocabas^a, Johan Gustafsson^a, Mihail Anton^b, Pierre-Etienne Cholley^b, Shan Huang^b, Johan Gobom^d, Thomas Svensson^b, Mattias Uhlen^{e,f,g}, Henrik Zetterberg^{d,h,i,j}, and Jens Nielsen^{a,e,k,1}

^aDepartment of Biology and Biological Engineering, Chalmers University of Technology, SE-412 96 Gothenburg, Sweden; ^bDepartment of Biology and Biological Engineering, National Bioinformatics Infrastructure Sweden, Science for Life Laboratory, Chalmers University of Technology, SE-412 96 Gothenburg, Sweden; ^cWallenberg Center for Molecular and Translational Medicine, University of Gothenburg, 405 30 Gothenburg, Sweden; ^dDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, 431 30 Mölndal, Sweden; ^eNovo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, 2800 Kgs. Lyngby, Denmark; ^fDepartment of Protein Science, Science for Life Laboratory, KTH–Royal Institute of Technology, SE-100 44 Stockholm, Sweden; ^gWallenberg Center for Protein Research, KTH–Royal Institute of Technology, SE-100 44 Stockholm, Sweden; ^hClinical Neurochemistry Laboratory, Sahlgrenska University Hospital, 431 30 Mölndal, Sweden; ⁱDepartment of Neurodegenerative Disease, University College London Queen Square Institute of Neurology, London WC1E 6BT, United Kingdom; ^jUK Dementia Research Institute, University College London, London WC1E 6BT, United Kingdom; and ^kBiocenter, University of Copenhagen, DK-2200 Copenhagen, Denmark

Edited by Sang Yup Lee, Korea Advanced Institute of Science and Technology, Daejeon, South Korea, and approved June 15, 2021 (received for review February 5, 2021)

Genome-scale metabolic models (GEMs) are used extensively for analysis of mechanisms underlying human diseases and metabolic malfunctions. However, the lack of comprehensive and high-quality GEMs for model organisms restricts translational utilization of omics data accumulating from the use of various disease models. Here we present a unified platform of GEMs that covers five major model animals, including Mouse1 (*Mus musculus*), Rat1 (*Rattus norvegicus*), Zebrafish1 (*Danio rerio*), Fruitfly1 (*Drosophila melanogaster*), and Worm1 (*Caenorhabditis elegans*). These GEMs represent the most comprehensive coverage of the metabolic network by considering both orthology-based pathways and species-specific reactions. All GEMs can be interactively queried via the accompanying web portal Metabolic Atlas. Specifically, through integrative analysis of Mouse1 with RNA-sequencing data from brain tissues of transgenic mice we identified a coordinated up-regulation of lysosomal GM2 ganglioside and peptide degradation pathways which appears to be a signature metabolic alteration in Alzheimer's disease (AD) mouse models with a phenotype of amyloid precursor protein overexpression. This metabolic shift was further validated with proteomics data from transgenic mice and cerebrospinal fluid samples from human patients. The elevated lysosomal enzymes thus hold potential to be used as a biomarker for early diagnosis of AD. Taken together, we foresee that this evolving open-source platform will serve as an important resource to facilitate the development of systems medicines and translational biomedical applications.

genome-scale model | animal model | Alzheimer's disease | A β deposition | translational medicine

Animal models have long been utilized as a fundamental tool for translational research in recapitulating phenotypic syndromes, clarifying underlying mechanisms, and translating biomedical discoveries into effective clinical treatments for human disease (1). Small rodents, including mouse (*Mus musculus*) and rat (*Rattus norvegicus*), account for 90% of the tens of millions of animals used annually in medical research (2, 3), and transgenic mice in particular are the most commonly used models for a plethora of human diseases including cancers, neurodegenerative dementia, diabetes, and many other metabolic disorders (4). In addition, with their unique anatomical and physiological features transgenic zebrafish (*Danio rerio*) and invertebrate models, such as the fruit fly (*Drosophila melanogaster*) and Nematoda worm (*Caenorhabditis elegans*), have been used for many years as inexpensive alternatives for studying human diseases through genetic manipulation of ortholog genes (5, 6). It is also important to note that nearly all the fundamental aspects of biology have been derived from the study of model organisms (7).

A genome-scale metabolic model (GEM) is a mathematical representation of the metabolism for an organism and it provides extensive gene–reaction–metabolite connectivity via two matrices: the *S* matrix for associating metabolites to reactions and the *rxnGeneMat* matrix associating reactions to corresponding enzymes and genes (8). Given that many human diseases, including cancer, type II diabetes, and many liver- and pancreas-related diseases can be attributed to metabolic disorders (9), human GEMs have been used to describe the metabolic conditions of specific tissues and cell types at the systems level with the integration of omics data (10–13). For the purpose of clarity, henceforth “GEM” is used here to refer to a computational metabolic model, and “model” refers to a transgenic animal developed for studying human disease.

The use of animal models together with GEMs poses an attractive approach to studying human disease. For example, mouse GEMs have previously been applied to investigate the influences of gut microbiota on host metabolism (14). To date, there have

Significance

Animal models and genome-scale metabolic models (GEMs) are two important tools for studying human diseases, but a proper integration of the two is lacking. To bridge them, we developed a reproducible and systematic framework by which the GEMs for major model animals are reconstructed and maintained. Due to the shared namespace, biological insights can be inferred from comparative analysis of the omics data from different animal models of the same disease. The drug targets and biomarkers derived from integrative metabolic analysis can thus be validated and translated to treatments and/or diagnostic methods. As an example, we demonstrated their utility in discovering potential biomarkers for early diagnosis of Alzheimer's disease, where there is a lack of effective diagnostics and treatments.

Author contributions: H.W., P.K., J. Gustafsson, M.A., H.Z., and J.N. designed research; H.W., J.L.R., P.K., J. Gustafsson, M.A., P.-E.C., and S.H. performed research; T.S., M.U., and J.N. contributed new reagents/analytic tools; H.W., J.L.R., J. Gustafsson, M.A., P.-E.C., J. Gobom, H.Z., and J.N. analyzed data; and H.W., J.L.R., P.K., J. Gustafsson, M.A., H.Z., and J.N. wrote the paper.

The authors declare no competing interest.

This article is a PNAS Direct Submission.

This open access article is distributed under [Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 \(CC BY-NC-ND\)](https://creativecommons.org/licenses/by-nc-nd/4.0/).

¹To whom correspondence may be addressed. Email: nielsenj@chalmers.se.

This article contains supporting information online at <https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2102344118/-DCSupplemental>.

Published July 19, 2021.

been a few existing GEMs for model animals, including MMR (14) and iMM1865 (15) for mouse, iRno (16) for rat, ZebraGEM (17, 18) for zebrafish, and iCEL1273 and iCEL1314 for worm (19, 20). However, these GEMs have not been developed and publicly curated to the same extent as that of yeast (21) and human (11). Their limited coverage in metabolic pathways and incompatible nomenclatures impede cross-species validation of biological discoveries and translational applications from animal models to human patients.

Recently, an open and version-controlled workflow has been introduced during the development of the most comprehensive yeast and human GEM, Yeast8 (21) and Human1 (11), respectively, which present high-quality templates to develop new GEMs in a systematic and reproducible manner. Databases such as MGD (22), FlyBase (23), ZFIN (24), and WormBase (25) that provide organism-specific annotation and human orthologs have been recently integrated into a centralized portal, the Alliance of Genome Resources (26), for consistent annotation and curation of gene ontology in relation to the human counterparts. Through channeling these reliable data sources we here present a unified GEM platform for mouse, rat, zebrafish, fruit fly, and worm. The derived GEMs (Mouse1, Rat1, Zebrafish1, Fruitfly1, and Worm1, respectively) were reconstructed from a robust modeling pipeline that combines both the orthology-based metabolic network and species-specific pathways. To validate this approach, we conducted an extensive GEM comparison and gene essentiality analysis using available experimental data and demonstrated that our GEMs generally outperform the previous ones. We also showcased the usefulness of Mouse1 in systems medicine discovery by performing integrative analysis of omics data from mouse models of Alzheimer's disease (AD). We are confident that this versatile GEM platform covering all major model animals will greatly enhance the utilization of omics data from disease models in facilitating translational studies.

Results

GEM Reconstruction, Exploration, and Curation for Model Animals.

We developed a pipeline that combines various reliable data sources and generates a coherent collection of GEMs for major model animals, including mouse (*M. musculus*), rat (*R. norvegicus*), zebrafish (*D. rerio*), fruit fly (*D. melanogaster*), and Nematoda

worm (*C. elegans*) (Fig. 1 and *SI Appendix*, Fig. S1). In this pipeline, the open-curated generic human GEM, Human1 (11), was used as a template. The well-annotated orthologs and paralogs associated from human to the five model organisms, as well as evaluating features *bestForward*, *bestReverse*, and *methodCount* (the number of different methods used in determining the orthologs), were retrieved from the Alliance Genomes databases using the stringent criteria provided (26). All one-to-one pairs were kept, while the one-to-multiple pairs were filtered with the following criteria: 1) exclude the pairs that are neither *bestforward* nor *bestReverse* and 2) only keep the pairs that are both the best forward and reverse hits. If steps 1 and 2 exclude all hits for a query gene, then we retrieved and kept the ortholog pair(s) with the highest *methodCount*. Using the RAVEN toolbox (27), the species-specific reactions and metabolites for each animal were extracted from the KEGG (Kyoto Encyclopedia of Genes and Genomes) database and manually inspected for integration (*SI Appendix*). Here, we report the first releases of these simulation-ready animal GEMs as Mouse1, Rat1, Zebrafish1, Fruitfly1 and Worm1, respectively (Fig. 1 and *Dataset S1*).

These new GEMs were integrated into the accompanying web portal Metabolic Atlas (<https://metabolicatlas.org/>), which allows for interactive exploration and cross-species comparison of the GEMs through the GEM Browser, a tabular interface; the Map Viewer, a collection of manually curated two-dimensional maps and automated three-dimensional maps; and the Interaction Partners tool, a network view of gene-metabolite associations. Furthermore, the relational database (PostgreSQL) powering the Metabolic Atlas portal was replaced by a graph implementation (Neo4j), enabling new features such as GEM comparison via external identifiers. These improvements are released as Metabolic Atlas 2.0, which is open-source with the running website, graph database integration, upgraded three-dimensional viewer, and all data files publicly available (*SI Appendix*).

To facilitate open curation and continuous integration of biochemical knowledge from the research community, these GEMs are tightly integrated with GitHub (see *Data Availability*) in complying with the “standard-GEM” specifications (28), which defines a set of requirements and recommendations for versioning GEMs and structuring Git-based repositories.




Fig. 1. Genome-scale metabolic modeling for model animals. A reconstruction approach of combining (A) ortholog-GEMs derived from the Human1 template and (B) species-specific metabolic networks extracted from the KEGG database by the RAVEN package was used to obtain (C) the model animal GEMs that were deposited on GitHub according to the standard-GEM scheme (28).

GEM Comparison, Evaluation, and Validation. As generated by a coherent pipeline in which all primary identifiers belong to the same namespace, the new generic GEMs can be compared under a consistent scheme of subsystems (Fig. 24). Despite the reduction in the total number of reactions, Worm1 contained new phenylpropanoid biosynthesis pathway reactions, and the hormone biosynthesis pathway in *Fruitfly1* was augmented, after the integration of a species-specific metabolic network. Likewise, Mouse1 and Rat1 are capable of de novo synthesis of vitamin C (ascorbate), a metabolic feature retained in most rodent species but lost in humans (29). In addition, the primary identifiers of metabolites and reactions from the new GEMs were all provided with the MetaNetX identifiers (30) for convenient comparison and expansion.

To validate these newly developed GEMs, we conducted a systematic comparison with existing GEMs of the same species (Fig. 2 and Dataset S1). For each species, the newly generated GEMs obtained substantially expanded coverage in metabolic components of genes, reactions, and metabolites, as well as extended complex-subunit information (Fig. 2 B–F). An exception was the GEM BMID000000141998, which was produced from a fully automatic pipeline and included more genes and metabolites, but the quality of automatically generated GEMs is generally low due to lack of curation (31).

The quality of a GEM is often evaluated by predicting genes that are essential to the viability of the organism and comparing the predictions with experimental data. To validate our animal GEM reconstruction pipeline, a gene essentiality analysis was conducted for each species by comparing the predictive performance of new and previous GEMs (Fig. 2G and Dataset S2). In this analysis, the genes for a given GEM were individually knocked out in silico to identify those that are essential for biomass formation (cell viability). The prediction results were then compared with gene essentiality data retrieved from the Online Gene Essentiality (OGEE) database (32) to quantify the number of true and false positives and negatives. The Matthews correlation coefficient (MCC), a balanced metric of classification performance (33), was calculated for the GEMs of mouse, fruit fly, and worm, for which genome-scale experimental gene essentiality data were available (Dataset S2). Mouse1 demonstrated a substantial improvement in essentiality predictions (MCC = 0.158) compared to 0.09 and 0.03 for iMM1865 and MMR, respectively. *Fruitfly1* also showed a better predictive capacity than *FlySilico*, a simple GEM covering only central carbon, amino acid, lipid, and carbohydrate metabolism (31). The automatically generated GEM BMID000000141998 predicted all genes as nonessential and therefore had an undefined MCC value (Fig. 2G). For the worm GEMs, Worm1 displayed improved prediction performance compared to iCEL1273 (19) and equivalent to the very recent iCEL1314, from which by incorporating the pathway for Ascaroside biosynthesis and transportation (20). This further highlights the importance of curation and more complete coverage of metabolism in obtaining systems-level insights.

The MEMOTE scores (34), which were estimated from a series of tests on stoichiometric consistency, mass-balanced and blocked reactions, associated annotations, and so on, were used for benchmarking. The new GEMs outperformed the existing GEMs for each species with regard to MEMOTE scores (Fig. 2 B–F).

Integrative Metabolic Analysis of AD Models Using Mouse1. Due to many attractive features (small and easy to handle, prolific breeder, and amenable to genetic manipulation) of mice and high genomic similarity to human, mouse models exist for a substantial number of diseases (4). They are extremely useful in studying the conditions for which patient samples and experiments are unfeasible or unethical to obtain (e.g., neurodegenerative diseases). To date, there are ~200 different mouse models that have been developed for

understanding the mechanism of AD (35), which is the most prevalent dementia affecting millions of people worldwide (36).

To demonstrate the utility of the GEMs developed using our framework, Mouse1 was used to investigate different AD models through omics data integration and gene set analysis (Fig. 3 and SI Appendix, Figs. S2–S6). Using a detailed search of the GEO database (SI Appendix), a total of 11 high-quality RNA-sequencing (RNA-seq) datasets including both transgenic mice and wild-type controls with paired time points were selected from six representative AD models (Fig. 3A and B and Dataset S3). There were four amyloid precursor protein (APP) overexpression models that recapitulate the major AD pathology (i.e., the formation of intracellular plaques and tangles containing aggregated amyloid β (A β) peptide and hyperphosphorylated tau protein), as well as two Trem2KO models with a deleted Trem2 gene that had complete or partial absence of the A β deposition phenotype. To make the figures simple and easy to understand, the models APP^{swe}/PSEN1^{dE9} (line 85) and APP^{swe}/PSEN1^{dE9} (C57BL6) that have identical genotype but use different mouse strains were merged and the sample GEO IDs were consistently provided for clarification. Next, we applied the task-driven integrative network inference algorithm (tINIT) (37) to generate tissue- and cell-type-specific GEMs, which combine the metabolic network determined by the RNA-seq data of metabolic genes and the essential reactions required for all cell types (SI Appendix). A structural comparison showed that the GEMs from APP overexpression models are more homogeneous than those from Trem2KO models, regardless of tissue source, gender, and age (Fig. 3C and SI Appendix, Fig. S2). In contrast, the GEMs from Trem2KO model separated explicitly by cell types. GEMs from APP overexpression models were characterized by an enhanced coverage of pathways including cholesterol biosynthesis, beta oxidation of fatty acids, and amino acid metabolism but reduced coverage of biopterin metabolism (SI Appendix, Fig. S3). In addition, de novo synthesis of asparagine, cystine, and cysteine and energy-associated functions were reduced in Trem2KO model GEMs (SI Appendix, Fig. S4). Interestingly, the GEMs of the hybrid model that was developed by crossing the Trem2KO and APP^{swe} transgenic mice presented different metabolic features from both ascendants in reaction content (Fig. 3C and SI Appendix, Fig. S2), subsystem coverage (SI Appendix, Fig. S3), and metabolic task performance (SI Appendix, Fig. S4). In summary, the comparison of these context-specific GEMs revealed distinct metabolism between the neuronal cells of APP overexpression and Trem2KO models.

Enrichment analysis conducted with various gene-set collections also showed distinct metabolic differences between APP overexpression and Trem2KO models (SI Appendix, Fig. S5). Among the APP overexpression models, substantial expression profile changes were observed along with A β deposition, including the up-regulation of pathways in apoptosis, signaling, cholesterol homeostasis, innate immune system, allograft rejection, inflammatory and interferon response, and a number of energy metabolism and neurodegenerative diseases (SI Appendix, Fig. S5). To pinpoint the altered metabolic processes associated with A β deposition we performed comparative analysis of subsystems (SI Appendix, Fig. S6) and reporter metabolite gene sets (Fig. 3D). The oxidative phosphorylation, amino acid metabolism, fatty acid oxidation, and cholesterol metabolism were identified as prominently up-regulated during the progression of AD (SI Appendix, Fig. S6). This is consistent with the down-regulation of mitochondrial metabolite gene sets associated with energy metabolism in the AD models before the onset of A β deposition (Fig. 3D). The alteration patterns of these metabolic pathways were also consistent with that found in the previous enrichment analysis (SI Appendix, Fig. S5), as well as the tissue-specific GEM comparison (Fig. 3C and SI Appendix, Fig. S3). With gene–reaction–metabolite connectivity of GEMs, gene sets associated with each metabolite can be obtained and subjected to enrichment analysis that may reveal insights into






Fig. 2. Systematic comparison and evaluation of generic model animal GEMs. (A) Significantly altered subsystems with deviated reaction content between the newly generated GEMs and Human1. The color indicates the percent difference in the number of reactions within each subsystem for a GEM compared to the mean number of reactions in that subsystem across all GEMs. Radar plots showing the comparison in the numbers of reactions, metabolites, genes, and enzyme complexes that have a GPR with "and" relation, as well as benchmarking MEMOTE scores between the GEMs for (B) mouse, (C) rat, (D) zebrafish, (E) fruit fly, and (F) worm. (G) Evaluation of gene essentiality prediction performance among GEMs of mouse, fruit fly, and worm using the MCC, which scores the relative amount of true and false positive and negative predictions of gene essentiality.


A Transgenic AD mice and wild type controls with paired time points



B Selected mouse models and datasets



C Structural comparison tissue/cell-type specific GEMs



D Reporter metabolite analysis




Fig. 3. RNA-seq data integration and gene set analysis using Mouse1. (A) Various AD models of transgenic mice have been developed to recapitulate the pathology of A β deposition and subsequent phenotypes of subsequent neuroinflammation and cognitive impairment. (B) RNA-seq datasets from transgenic and wild-type mice with paired time points were selected for studying the metabolic changes associated with AD progression. The colored symbols are used to depict the different datasets and their sampling time points in relation to the onset and progression of A β deposition, which is illustrated by a shaded background (Dataset S3). (C) Structural comparison of tissue/cell type-specific GEMs using *t*-distributed stochastic neighbor embedding (tSNE) analysis. (D) Reporter metabolite gene set analysis using Mouse1. The log-transformed P_{enrich} value quantifies the significance of substantially up- (in positive values) or down-regulated (in negative values) gene sets between diseased and normal conditions. Subcellular compartment is indicated in brackets, in which l, m, and c refer to lysosome, mitochondrion, and cytosol, respectively. *The full names of the CoA metabolites are (6Z,9Z,12Z,15Z)-octadecatetraenoyl-CoA, (5Z,8Z,11Z,14Z,17Z)-eicosapentaenoyl-CoA, and (7Z)-octadecadienoyl-CoA, respectively.

network level alterations of given expression data. Notably, the gene sets of reporter metabolites (GM2A, H+, Pi, H₂O, ADP, and ATP) associated with lysosome (Dataset S3) were uniformly enriched in the APP overexpression models after A β deposition but absent from the hybrid Trem2 KO (KOMP) \times APPPS1 model (Fig. 3D).

A β Accumulation Activates Gene Expression in Lysosomal Pathways of GM2 Gangliosides and Peptide Degradation. By integrative analysis of reporter metabolite gene sets with Mouse1 we discovered an up-regulated GM2A-centric lysosomal subnetwork shared between APP overexpression models (Fig. 4 and SI Appendix, Fig. S7). This

subnetwork was not enriched in the data from Trem2KO models, as well as the conditions prior to A β plaque formation in APP overexpression models (SI Appendix, Fig. S8). It therefore appeared to be the signature response induced specifically by A β accumulation. By inspecting the expression pattern of the lysosomal genes across the collected AD models we confirmed their consistent up-regulation in APP overexpression models and only after the onset of A β deposition (Fig. 5A). Within the APP models, a higher magnitude of fold change of lysosomal genes was observed in APPS1 compared to APP23 and APP^{swe}/PSEN1dE9. Among the four time points from the APP23 model data (GSE80465), the up-regulation of the lysosomal genes peaked at 18 mo, whereas they appeared to slightly decrease in a later stage at 24 mo. In contrast, only marginal changes were observed in the APP^{swe}/PSEN1dE9 (line 85) model (GSE136861), which were sampled

with four time points (2, 4, 5, and 6 mo) when A β plaques have not been formed in the brain of transgenic mice (Dataset S3).

Validation of Activated Lysosomal Degradation Pathways Using Proteomics Data from AD Models. To validate the activation of the lysosomal degradation pathways at the protein level we reanalyzed proteomics datasets obtained from brain tissues of another five APP overexpression models: hAPP, hAPP/PS1, 5xFAD, ADLP^{ADP}, and ADLP^{APP/PS1} (Fig. 5B and Dataset S3). Despite the different methods of mass spectrometric detection and quantification, a concerted up-regulation of the candidate lysosomal digestive enzymes, except Nme4, was observed among the differentially expressed proteins between transgenic versus wild-type mice at different time points (Fig. 5C). In 5xFAD, ADLP^{ADP}, and ADLP^{APP/PS1} models, AD progression was clearly accompanied by an increase of these lysosomal proteins in fold




Fig. 4. Integrative analysis of reporter metabolite gene sets with Mouse1. The up-regulation of a GM2A-centric subnetwork in lysosome is identified as a signature response to in APP overexpression models: (A) APPS1, (B) APP^{swe}/PSEN1dE9, and (C) APP23. This subnetwork, indicated by a dashed box, was found to be the most significant and consistent metabolic change to A β deposition. The nodes depict significantly changed reporter metabolite gene sets (cutoff: $P < 0.002$), each of which comprises all genes associated with reactions in which one metabolite is involved. The node color reflects directionality score that indicates the overall differential direction of the gene set, ranging from down- (blue) to up-regulation (red). The node sizes are proportional to the $-\log_{10}p$ values of corresponding gene sets, and the edge width indicates the number of reactions shared by the metabolites. (D) The diagram depicts the lysosomal degradation pathways that were detected from the elevated mouse genes through integrative analysis.




Fig. 5. Validation of elevated lysosomal enzymes at the RNA and protein level. (A) Log₂ fold changes of lysosomal genes (*Gm2a*, *Hexa*, *Hexb*, *Ctsb*, *Ctsc*, *Ctsd*, *Ctsf*, *Ctss*, *Ctsz*, and *Nme4*) that are involved in GM2 ganglioside and peptide degradation. The data from each AD model are displayed in the order of sampling time, while the onset of A β deposition is indicated by a dashed red line. (B) Bar plot showing the number of significantly ($P < 0.05$) up-regulated lysosomal enzymes from five APP overexpression mouse models (hAPP, hAPP/PS1, 5xFAD, ADL^{APPS1}, and ADL^{PAPT}) (Dataset S4). (C) Heat maps showing the fold changes of these significantly up-regulated lysosomal enzymes along AD progression.

changes compared to the wild-type conditions. This suggests the potential application of their corresponding human orthologs, such as CTSS, as biomarkers for early diagnosis.

Investigation of Lysosomal Peptide Concentrations in Cerebrospinal Fluid Samples of AD Patients. Since our approach ensured a consistent namespace and nomenclature between Human1 and new animal GEMs, this enables convenient translation of results from animal model experiments to human validation. Consequently, we sought to investigate the expression levels of these lysosomal enzymes in human samples. By analyzing a dataset from a recent study that quantified 51 targeted peptides in the cerebrospinal fluid samples from AD patients and healthy controls (38), we found that peptides from GM2A, CTSS, and CTSD were significantly enriched in AD patients compared to those from

healthy individuals (SI Appendix, Fig. S9), supporting the association of altered lysosomal function in AD patients.

Discussion

In this study we presented a robust animal GEM development pipeline with which the most comprehensive GEMs (Mouse1, Rat1, Zebrafish1, Fruitfly1, and Worm1) for five major model animals were generated and maintained (Fig. 1 and SI Appendix, Fig. S1). With significantly expanded coverage of metabolic components compared to previously reported GEMs (Fig. 2 and Dataset S1), these new GEMs collectively serve as a coherent platform allowing systematic integration of high-throughput omics data from a wealth of disease models. These GEMs, capturing both the orthology-based metabolic network and species-specific pathways (Fig. 1) that can be interactively queried through the accompanying web portal Metabolic Atlas (11),

will evolve as a continuously expanding knowledgebase for the study of animal metabolism.

We demonstrated a specific case of using Mouse1 through a systems biology approach with omics data integration (Fig. 3). There exists an abundance of rodent models developed by introducing AD risk genes (35) that include APP and presenilin 1 and 2 (PSEN1 and PSEN2), which have been determined to cause A β deposition in familial forms of AD (39), and other susceptible genes (e.g., TREM2) that were associated with sporadic AD (40, 41). Both APP overexpression and Trem2KO models, as well as the hybrid one Trem2KO \times APPS1 (42), were investigated to evaluate their metabolic features in terms of the different genetic backgrounds (Fig. 3 and *SI Appendix*, Figs. S2–S4). The illustration of model-specific changes revealed their distinct metabolism, supporting the claim that each model can only recapitulate partial AD pathologies (43). This further stresses the necessity of an integrative evaluation of different transgenic animals, and our GEM-based *in silico* analysis was shown to be very useful in characterizing various animal models of the same disease in their metabolic capacity and guiding downstream investigations toward targeted clinical application.

A β plaque formation increases with age in both transgenic mice and AD patients (6), making APP overexpression models useful tools in elucidating the temporal development of AD in human brain (35). Assisted by the comprehensive coverage of metabolic genes in Mouse1, a subnetwork of lysosomal degradation pathways was identified as a signature response to A β deposition across the APP overexpression models (Fig. 4 and *SI Appendix*, Fig. S7). The lysosomal pathways appeared to be activated immediately with the onset of A β deposition and sustained throughout the progression of AD in transgenic mice (Fig. 5). The increased transcription and translation of individual lysosomal components were previously detected in brains of AD and other neurodegenerative disease patients (44). This is consistent with the observation of reduced A β levels in the brain of transgenic mice after *in vivo* up-regulation of lysosomal activities (45). In particular, our findings address lysosomal genes hydrolyzing GM2 gangliosides and peptides (Fig. 4D), whose homeostasis in neurons is essential for brain maintenance (46). Gangliosides are abundant in brain tissue and constitute ~10 to 12% of the lipid content in neuronal membranes (47). The content and composition of gangliosides decrease dramatically during aging (48). The *GM2A*, *HEXA*, and *HEXB* genes encode enzymes responsible for degradation of GM2 gangliosides, mutations obstructing this pathway induce neurodegenerative disorders, including Tay–Sachs disease, AB variant, and Sandhoff disease (49). Similarly, cysteine cathepsins CtsB/L have been demonstrated as essential in lysosomal degradation of A β peptides in mouse embryonic fibroblasts (50). *In vitro* screening also showed that CtsB and CtsL can proteolyze α -synuclein amyloid fibrils that are closely associated with neurodegeneration in parkinsonian disorders, while CtsD requires the assistance of anionic lipids for the hydrolysis (51). Collectively, a strong correlation between AD and endolysosomal activities has been established with a growing number of studies. Previously, genetic deficiency of lysosomal genes was speculated as the cause of endolysosomal and autophagic dysfunction that subsequently drives AD progression (52). Using a systematic analysis of AD models with and without A β plaques, however, our results suggest that up-regulation of lysosomal degradation pathways occurs downstream of A β deposition, such that elevated expression of lysosomal genes is a result of AD pathogenesis rather than a cause. Also, lysosomal dysfunction appears to be involved as a cascading effect of A β deposition and worth continued exploration.

Biomarkers for an early diagnosis are urgently needed for AD due to the lack of effective treatments (53). There are currently

three well-established biomarkers of lower A β 42 levels and higher levels of total and phosphorylated tau for AD diagnosis (54). By translating the metabolic alterations obtained from analyzing AD models with Mouse1 (Fig. 5), here we presented a collection of nine lysosomal enzymes as potential biomarkers, of which CSTD has been previously verified in cerebrospinal fluid (55) and plasma samples (56), while the others represent new candidates. Our statistical analysis showed that the peptides of CTSB, CTSD, and GM2A in cerebrospinal fluid samples of AD patients are significantly increased compared to those in healthy controls (*SI Appendix*, Fig. S9). In addition, the rapid elevation of expressed lysosomal genes following A β deposition in mouse models also suggests that these lysosomal enzymes may be up-regulated in the prodromal phase of AD (Fig. 5). This is in good agreement with the longitudinal analysis of plasma CSTD levels, which were sampled from the same patients at preclinical phase and after diagnosed as AD (with an interval of 1 to 10 y), and both were significantly elevated in comparison to that in healthy controls (56). Taken together, the presented lysosomal enzymes identified with altered expression by the approach of systems medicines constitute potential body fluid biomarkers that may be utilized for early-stage AD diagnosis.

In summary, we presented tissue- and time-dependent variations of AD mice and reported candidate biomarkers through integrative analysis of omics data with animal GEMs. By associating gene expression changes to subsystem and metabolite levels, this study demonstrated how results from model organism can be translated to clinical implications in human. Next, it is expected that the discovered disease-specific patterns and biomarkers could be inspected with large-scale comparative analysis of human datasets and body fluid samples for further verification. For quantitative flux predictions, we suggest contextualizing (e.g., tINIT) these GEMs with omics data and/or using the GECKO enzyme-constraint framework (57). Along with the rapidly growing omics data, we are confident that the set of animal GEMs will be a valuable platform assisting translational studies toward developing clinical treatments for a wide range of human diseases.

Materials and Methods

All the materials and methods are detailed in *SI Appendix*: generation, comparison, and evaluation of animal GEMs; development of Metabolic Atlas 2.0; RNA-seq data retrieval and differential expression analysis; gene set and network integrative analysis; proteomics data investigation; and statistical analyses. All GEM simulations were carried out in MATLAB using RAVEN toolbox (27) with the Gurobi solver (Gurobi Optimization, LLC).

Data Availability. The GEMs for Mouse1, Rat1, Zebrafish1, Fruitfly1, and Worm1 are available on GitHub at <https://github.com/SysBioChalmers/Mouse-GEM>, <https://github.com/SysBioChalmers/Rat-GEM>, <https://github.com/SysBioChalmers/Zebrafish-GEM>, <https://github.com/SysBioChalmers/Fruitfly-GEM>, and <https://github.com/SysBioChalmers/Worm-GEM>, respectively. The code for GEM development is available at <https://github.com/SysBioChalmers/Human-GEM>. The tissue- and cell-type-specific GEMs for transgenic mice and code for integrative analysis are available at <https://github.com/SysBioChalmers/Mouse-GEM>. All other data are available in supporting information.

ACKNOWLEDGMENTS. We thank Leif Våremo, Francesco Gatto, Sinisa Bratulic, Rasool Saghaleyni, Fariba Roshanzamir, and Xin Chen for valuable discussions. The computations were performed on resources provided by the Swedish National Infrastructure for Computing at C3SE. This work was supported by the Knut and Alice Wallenberg Foundation and the Chalmers Foundation. H.Z. is a Wallenberg Scholar supported by grants from the Swedish Research Council (2018-02532), the European Research Council (681712), Swedish State Support for Clinical Research (ALFGBG-720931), the Alzheimer Drug Discovery Foundation (201809-2016862), and the UK Dementia Research Institute at University College London.

1. A. P. Beck, D. K. Meyerholz, Evolving challenges to model human diseases for translational research. *Cell Tissue Res.* **380**, 305–311 (2020).
2. K. A. Phillips *et al.*, Why primate models matter. *Am. J. Primatol.* **76**, 801–827 (2014).
3. M. Daneshian, F. Busquet, T. Hartung, M. Leist, Animal use for science in Europe. *ALTEX* **32**, 261–274 (2015).
4. N. Rosenthal, S. Brown, The mouse ascending: Perspectives for human-disease models. *Nat. Cell Biol.* **9**, 993–999 (2007).
5. E. E. Davis, N. Katsanis, *Zebrafish: A Model System to Study the Architecture of Human Genetic Disease* (Elsevier, 2017).
6. T. M. Dawson, T. E. Golde, C. Lagier-Tourenne, Animal models of neurodegenerative diseases. *Nat. Neurosci.* **21**, 1370–1379 (2018).
7. S. Fields, M. Johnston, Whither model organism research? *Science (80-)* **307**, 1885–1886 (2005).
8. J. Nielsen, Systems biology of metabolism. *Annu. Rev. Biochem.* **86**, 245–275 (2017).
9. J. Nielsen, Systems biology of metabolism: A driver for developing personalized and precision medicine. *Cell Metab.* **25**, 572–579 (2017).
10. R. Agren *et al.*, Reconstruction of genome-scale active metabolic networks for 69 human cell types and 16 cancer types using INIT. *PLoS Comput. Biol.* **8**, e1002518 (2012).
11. J. L. Robinson *et al.*, An atlas of human metabolism. *Sci. Signal.* **13**, 1–12 (2020).
12. N. E. Lewis, A. M. Abdel-Haleem, The evolution of genome-scale models of cancer metabolism. *Front. Physiol.* **4**, 237 (2013).
13. K. Yizhak, B. Chaneton, E. Gottlieb, E. Ruppin, Modeling cancer metabolism on a genome scale. *Mol. Syst. Biol.* **11**, 817 (2015).
14. A. Mardinoglu *et al.*, The gut microbiota modulates host amino acid and glutathione metabolism in mice. *Mol. Syst. Biol.* **11**, 834 (2015).
15. S. Khodaei, Y. Asgari, M. Totonchi, M. H. Karimi-Jafari, iMM1865: A new reconstruction of mouse genome-scale metabolic model. *Sci. Rep.* **10**, 6177 (2020).
16. E. M. Blais *et al.*, Reconciled rat and human metabolic networks for comparative toxicogenomics and biomarker predictions. *Nat. Commun.* **8**, 14250 (2017).
17. M. Bekaert, Reconstruction of Danio rerio metabolic model accounting for subcellular compartmentalisation. *PLoS One* **7**, e49903 (2012).
18. L. van Steijn, F. J. Verbeek, H. P. Spaik, R. M. H. Merks, Predicting metabolism from gene expression in an improved whole-genome metabolic network model of *Danio rerio*. *Zebrafish* **16**, 348–362 (2019).
19. L. S. Yilmaz, A. J. M. Walhout, *Caenorhabditis elegans* genome-scale metabolic network model. *Cell Syst.* **2**, 297–311 (2016).
20. L. S. Yilmaz *et al.*, Modeling tissue-relevant *Caenorhabditis elegans* metabolism at network, pathway, reaction, and metabolite levels. *Mol. Syst. Biol.* **16**, e9649 (2020).
21. H. Lu *et al.*, A consensus *S. cerevisiae* metabolic model Yeast8 and its ecosystem for comprehensively probing cellular metabolism. *Nat. Commun.* **10**, 3586 (2019).
22. C. J. Bult *et al.*, Mouse Genome Database (MGD) 2019. *Nucleic Acids Res.* **47** (D1), D801–D806 (2019).
23. A. Larkin *et al.*, FlyBase: Updates to the *Drosophila melanogaster* knowledge base. *Nucleic Acids Res.* **49**, D899–D907 (2020).
24. L. Ruzicka *et al.*, The Zebrafish Information Network: New support for non-coding genes, richer Gene Ontology annotations and the Alliance of Genome Resources. *Nucleic Acids Res.* **47**, D867–D873 (2019).
25. T. W. Harris *et al.*, WormBase: A modern model organism information resource. *Nucleic Acids Res.* **48**, D762–D767 (2020).
26. J. Agapite *et al.*, Alliance of Genome Resources Portal: Unified model organism research platform. *Nucleic Acids Res.* **48**, D650–D658 (2020).
27. H. Wang *et al.*, RAVEN 2.0: A versatile toolbox for metabolic network reconstruction and a case study on *Streptomyces coelicolor*. *PLoS Comput. Biol.* **14**, e1006541 (2018).
28. M. Anton, ulfliebal, H. Wang, MetabolicAtlas/Standard-GEM: Standard-GEM 0.5 (Version 0.5, Zenodo, 2021).
29. M. Nishikimi, T. Kawai, K. Yagi, Guinea pigs possess a highly mutated gene for L-gulonolactone oxidase, the key enzyme for L-ascorbic acid biosynthesis missing in this species. *J. Biol. Chem.* **267**, 21967–21972 (1992).
30. S. Moretti *et al.*, MetaNetX/MNXref—Reconciliation of metabolites and biochemical reactions to bring together genome-scale metabolic networks. *Nucleic Acids Res.* **44**, D523–D526 (2016).
31. J. W. Schönborn, L. Jehrke, T. Mettler-Altmann, M. Beller, FlySilico: Flux balance modeling of *Drosophila* larval growth and resource allocation. *Sci. Rep.* **9**, 17156 (2019).
32. W. H. Chen, G. Lu, X. Chen, X. M. Zhao, P. Bork, OGEE v2: An update of the online gene essentiality database with special focus on differentially essential genes in human cancer cell lines. *Nucleic Acids Res.* **45**, D940–D944 (2017).
33. B. W. Matthews, Comparison of the predicted and observed secondary structure of T4 phage lysozyme. *BBA - Protein Struct.* **405**, 442–451 (1975).
34. C. Lieven *et al.*, MEMOTE for standardized genome-scale metabolic model testing. *Nat. Biotechnol.* **38**, 272–276 (2020).
35. ALZFORUM, AD research models. <https://www.alzforum.org/research-models>. Accessed 22 June 2020.
36. E. Nichols *et al.*, Global, regional, and national burden of Alzheimer's disease and other dementias, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. *Lancet Neurol.* **18**, 88–106 (2019).
37. R. Agren *et al.*, Identification of anticancer drugs for hepatocellular carcinoma through personalized genome-scale metabolic modeling. *Mol. Syst. Biol.* **10**, 721 (2014).
38. S. Sjödin *et al.*, Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer's and Parkinson's disease. *Alzheimers Res. Ther.* **11**, 82 (2019).
39. L. M. Bekris, C. E. Yu, T. D. Bird, D. W. Tsuang, Genetics of Alzheimer disease. *J. Geriatr. Psychiatry Neurol.* **23**, 213–227 (2010).
40. T. Jonsson *et al.*, Variant of TREM2 associated with the risk of Alzheimer's disease. *N. Engl. J. Med.* **368**, 107–116 (2013).
41. R. Guerreiro *et al.*, TREM2 variants in Alzheimer's disease. *N. Engl. J. Med.* **368**, 117–127 (2013).
42. T. R. Jay *et al.*, TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer's disease mouse models. *J. Exp. Med.* **212**, 287–295 (2015).
43. J. Verheijen, K. Sleegers, Understanding Alzheimer disease at the interface between genetics and transcriptomics. *Trends Genet.* **34**, 434–447 (2018).
44. A. Yamamoto, Z. Yue, Autophagy and its normal and pathogenic states in the brain. *Annu. Rev. Neurosci.* **37**, 55–78 (2014).
45. Q. Xiao *et al.*, Neuronal-targeted TFEB accelerates lysosomal degradation of app, reducing A β generation and amyloid plaque pathogenesis. *J. Neurosci.* **35**, 12137–12151 (2015).
46. S. Frere, I. Slutsky, Alzheimer's Disease: from firing instability to homeostasis network collapse. *Neuron* **97**, 32–58 (2018).
47. T. Kolter, Ganglioside Biochemistry. *ISRN Biochem.*, 1–36 (2012).
48. K. Segler-Stahl, J. C. Webster, E. G. Brunngraber, Changes in the concentration and composition of human brain gangliosides with aging. *Gerontology* **29**, 161–168 (1983).
49. M. B. Cachon-Gonzalez, E. Zaccariotto, T. M. Cox, Genetics and therapies for GM2 gangliosidosis. *Curr. Gene Ther.* **18**, 68–89 (2018).
50. S. Cermak *et al.*, Loss of Cathepsin B and L leads to lysosomal dysfunction, NPC-Like cholesterol sequestration and accumulation of the key Alzheimer's proteins. *PLoS One* **11**, e0167428 (2016).
51. R. P. McGlinchey, J. C. Lee, Cysteine cathepsins are essential in lysosomal degradation of α -synuclein. *Proc. Natl. Acad. Sci. U.S.A.* **112**, 9322–9327 (2015).
52. L. S. Whyte, A. A. Lau, K. M. Hemsley, J. J. Hopwood, T. J. Sargeant, Endo-lysosomal and autophagic dysfunction: A driving factor in Alzheimer's disease? *J. Neurochem.* **140**, 703–717 (2017).
53. E. Dolgin, How to defeat dementia. *Nature* **539**, 156–158 (2016).
54. B. Olsson *et al.*, CSF and blood biomarkers for the diagnosis of Alzheimer's disease: A systematic review and meta-analysis. *Lancet Neurol.* **15**, 673–684 (2016).
55. A. L. Schwagerl *et al.*, Elevated levels of the endosomal-lysosomal proteinase cathepsin D in cerebrospinal fluid in Alzheimer disease. *J. Neurochem.* **64**, 443–446 (1995).
56. E. J. Goetzl *et al.*, Altered lysosomal proteins in neural-derived plasma exosomes in preclinical Alzheimer disease. *Neurology* **85**, 40–47 (2015).
57. B. J. Sánchez *et al.*, Improving the phenotype predictions of a yeast genome-scale metabolic model by incorporating enzymatic constraints. *Mol. Syst. Biol.* **13**, 935 (2017).